Brainstorm cell therapeutics submits ind amendment to fda, paving the way for phase 3b trial of nurown® in als

New york , april 10, 2025 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading biotechnology company developing cutting-edge cell therapies for neurodegenerative diseases, today announced the submission of an investigational new drug (ind) amendment to the u.s. food and drug administration (fda) for nurown®, the company's autologous mesenchymal stem cell therapy for amyotrophic lateral sclerosis (als). this important milestone sets the stage for the initiation of brainstorm's highly anticipated phase 3b clinical trial, which has been designed in collaboration with the fda under a special protocol assessment (spa).
BCLI Ratings Summary
BCLI Quant Ranking